Tesevatinib

also known as XL647 · KD019 · EXEL-7647 · KD-019 TOSYLATE · KD-020 · KD-020 TOSYLATE · Tesevatinib tosilate · TESEVATINIB TOSYLATE · +1 more

Small molecule targets EGFR, EPHB4, ERBB2, KDR via inhibition

Developed for: non-small cell lung carcinoma · autosomal dominant polycystic kidney disease · cancer · metastatic malignant neoplasm in the brain · autosomal recessive polycystic kidney disease · brain neoplasm · breast cancer · esophageal cancer
+4 more
· gastric cancer · glioblastoma · HER2 positive breast carcinoma · neoplastic meningitis
Investigated by: Kadmon Corporation, LLC · Kadmon, a Sanofi Company · Exelixis · NYU Langone Health

Trials 14 · a red edge is where a trial was stopped

today NCT03203642 · Ph 2 NCT03096080 · Ph 1 NCT02844439 · Ph 2 NCT02616055 · Ph 2 NCT02616393 · Ph 2 NCT02205463 · Ph 1 NCT02154529 · Ph 1/2 NCT01559363 · Ph 1/2 NCT01487174 · Ph 3 NCT00704392 · Ph 1 NCT00522145 · Ph 2 NCT00364780 · Ph 2 NCT00336765 · Ph 1 NCT00086528 · Ph 1

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT03096080	Aug 2017 → Sep 2019	autosomal recessive polycystic kidney disease	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 1	NCT02205463	Dec 2014 → Jul 2017	esophageal cancer, gastric cancer	NYU Langone Health	Withdrawn	No outcome recorded
Phase 1	NCT00704392	Jun 2008 → Dec 2009	breast cancer, non-small cell lung carcinoma	Exelixis	Withdrawn	No outcome recorded
Phase 1	NCT00336765	Jul 2006 → Aug 2010	cancer	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 1	NCT00086528	Jun 2004 → Jul 2007	cancer	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02154529	May 2014 → Sep 2015	HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain	Kadmon Corporation, LLC	Terminated	No outcome recorded
Phase 1/2	NCT01559363	Oct 2012 → Feb 2019	autosomal dominant polycystic kidney disease	Kadmon, a Sanofi Company	Completed	No outcome recorded
Phase 26 trials
Phase 2	NCT03203642	Oct 2017 → Jan 2022	autosomal dominant polycystic kidney disease	Kadmon, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT02844439	Jun 2016 → Apr 2020	brain neoplasm, glioblastoma	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 2	NCT02616055	Dec 2015 → Dec 2016	autosomal dominant polycystic kidney disease	Kadmon Corporation, LLC	Terminated	No outcome recorded
Phase 2	NCT02616393	Nov 2015 → Apr 2018	metastatic malignant neoplasm in the brain, neoplastic meningitis, non-small cell lung carcinoma	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 2	NCT00522145	May 2007 → Oct 2009	non-small cell lung carcinoma	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 2	NCT00364780	Jul 2006 → May 2010	non-small cell lung carcinoma	Kadmon Corporation, LLC	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT01487174	Dec 2011 → Jul 2013	non-small cell lung carcinoma	Kadmon Corporation, LLC	Terminated	No outcome recorded

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

Field	Value	Cited text
Known as	Tesevatinib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02616393 ↗ 6 NCT02844439 ↗ NCT02616055 ↗ NCT03096080 ↗ NCT02154529 ↗ NCT01559363 ↗ NCT03203642 ↗
Known as	EXEL-7647	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	KD-019 TOSYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	KD-020	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	KD-020 TOSYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	KD019	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02205463 ↗ 1 NCT01487174 ↗
Known as	Tesevatinib tosilate	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	TESEVATINIB TOSYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	Xl-647 tosylate	ChEMBL registry synonym — accepted as the source's own label CHEMBL3544983 ↗
Known as	XL647	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00522145 ↗ 4 NCT00364780 ↗ NCT00336765 ↗ NCT00704392 ↗ NCT00086528 ↗
Action	Inhibit	“multiple receptor tyrosine kinase (RTK) inhibitor” NCT00336765 ↗
Modality	Small molecule	“XL647 is a small molecule” NCT00364780 ↗ 1 CHEMBL3544983 ↗
Route	Oral	“Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD” NCT00086528 ↗
Target	EGFR	“multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4)” NCT00336765 ↗
Target	EphB4	“multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4)” NCT00336765 ↗
Target	ErbB2	“multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4)” NCT00336765 ↗
Target	VEGFR2	“multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4)” NCT00336765 ↗